PDS Biotechnology Corporation (PDSB) stock forecast & analysis
0.8055
NasdaqCM · USD
Down: -0.0367, -4.4%
0.8261Up: +0.0206, +2.6%
4 analyses
- Open
- 0.8300
- Previous close
- 0.8422
- Day range
- 0.7512 – 0.9000
- 52-week range
- 0.1950 – 1.55
- Volume (shares)
- 18.68M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 72.47M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.45
- Market cap
- 58.38M
Market Scanner’s AI analysis of PDS Biotechnology Corporation (PDSB), updated September 2026: PDSB's recent analyses covered a sharp price surge driven by financing news and billionaire investment, juxtaposed against persistent net losses and negative shareholder equity.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of PDS Biotechnology Corporation (PDSB) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
PDSB's recent analyses covered a sharp price surge driven by financing news and billionaire investment, juxtaposed against persistent net losses and negative shareholder equity.
Recent analyses for PDSB examined a significant, rapid price increase, with market indicators showing strong short-term momentum and overbought conditions. This surge coincided with news of substantial equity financing, including billionaire investment, and the appointment of a notable board member. However, the company's financial fundamentals revealed consistent net losses, declining assets, and negative shareholder equity across multiple reporting periods.
PDSB news & sentiment
News reports indicated a positive trend for PDSB, highlighted by announcements of significant equity financing and a notable board appointment, which appeared to positively impact the stock price and led to its outperformance against competitors. Social media discussion was not covered in the provided notes.
PDSB technical picture
Price action showed strong short-term upward momentum with significant 7-day and 30-day gains, while longer-term trends indicated a downtrend. Technical indicators frequently signaled overbought conditions with high momentum readings, though some analyses noted divergences between price action and buying pressure indicators.
Fundamentals
The company has consistently reported substantial net losses and negative operating cash flow across multiple years and quarters. Shareholder equity has declined significantly, becoming negative, while total assets decreased and total liabilities increased.
Factors discussed — upside
- Significant positive momentum in 7-day and 30-day price changes.
- Price trading well above 50-day and 200-day SMAs in some analyses.
- Announcement of initial closing of private financing rounds totaling up to $22.3 million and $22.6 million.
- Appointment of Dr. Patrick Soon-Shiong to the Board of Directors.
- Highlighted as outperforming competitors like MRNA, IOVA, and SLS, with rally fueled by billionaire investment.
Factors discussed — risks
- Negative total shareholder equity, decreasing significantly over reporting periods.
- Substantial increase in total liabilities alongside decreasing total assets.
- Consistent and substantial net losses reported annually and quarterly.
- Negative operating cash flow for the past four reported years.
- Price trading below 200-day SMA in some analyses, indicating a long-term downtrend.
- Market momentum and technical indicators
- Financing and investment news
- Financial performance and balance sheet health
- Biotechnology sector trends
Summary updated .
PDSB technical indicators
Common technical indicators for PDSB, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.50 | Price above |
| 10-day exponential moving average | 0.58 | Price above |
| Relative strength index (14-day) | 69.12 | Neutral |
| MACD line (12/26/9) | 0.0827 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -0.11 – 0.83 | Price inside the bands |
Analyses
Recent PDSB.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for PDS Biotechnology Corporation?
- Recent analyses highlighted significant positive price momentum, driven by substantial equity financing rounds and notable investor backing, alongside the appointment of a key board member. The company was also noted as outperforming certain competitors in the sector.
- What are the risks for PDS Biotechnology Corporation?
- The company's financial health shows persistent net losses and a decline in shareholder equity, accompanied by increasing liabilities and decreasing assets. Furthermore, operating cash flow has been negative for several years, and some analyses indicated a long-term downtrend in price relative to the 200-day moving average.
- Is PDS Biotechnology Corporation bullish or bearish?
- Recent AI analyses of PDS Biotechnology Corporation examined factors on both sides. Discussed upside: Recent analyses highlighted significant positive price momentum, driven by substantial equity financing rounds and notable investor backing, alongside the appointment of a key board member. The company was also noted as outperforming certain competitors in the sector. Discussed risks: The company's financial health shows persistent net losses and a decline in shareholder equity, accompanied by increasing liabilities and decreasing assets. Furthermore, operating cash flow has been negative for several years, and some analyses indicated a long-term downtrend in price relative to the 200-day moving average. These are descriptive observations, not a recommendation.
- What is the latest sentiment on PDS Biotechnology Corporation?
- News reports indicated a positive trend for PDSB, highlighted by announcements of significant equity financing and a notable board appointment, which appeared to positively impact the stock price and led to its outperformance against competitors. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse PDS Biotechnology Corporation?
- Every analysis of PDS Biotechnology Corporation runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh PDSB.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every PDSB.US report already in the library